Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Physicians who Treat Insomnia (US)

Council Members in this Study Group: 546

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Daniel Wynn, Director of Clinical Research, CONSULTANTS IN NEUROLOGY LTDDaniel Wynn

Director of Clinical Research
CONSULTANTS IN NEUROLOGY LTD
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple...

Alan Patterson

Obstetrician and Gynecologist
ALAN B PATTERSON MD, PA
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Alan Patterson, MD, is an Obstetrician and Gynecologist at Alan B Patterson MD, a private practice in Florida, since May 1991. Dr. Patterson was on the teaching staff at Methodist Hospital, Indianapolis, where he wrote many protocols for the residency...

Dick LeFave

Founder & Consultant
D&L Partners, LLC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Dick LeFave is the Founder of D&L Partners, an IT consulting firm. He retired from Sprint/Nextel in 2008 after serving as the Chief Information Officer for over 9 years. During that time, he was responsible for the strategic deployment of IT resources...

Dea Belazi, Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHMDea Belazi

Pharmacy Consultant
Dea Belazi, PharmD, MPH, PAHM
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Dea Belazi, PharmD, MPH, PAHM, is currently a Consultant working with health plans and pharmaceutical companies. Dr. Belazi is also a Consulting Practice Leader for Wolters Kluwer Health- Managed Care Group. Previously, he was the Senior Director of Pharmacy...

Robert Aris, Associate Professor of Medicine, University of North Carolina Chapel Hill - CCRobert Aris

Associate Professor of Medicine
University of North Carolina Chapel Hill - CC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Robert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Fampridine-SR -- anxiously awaited new MS therapeutic

June 2, 2009

Acorda’s Fampridine-SR Gets Priority Review | phoenix.corporate-ir.net

A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability.  Since disease modifying therapies have only been available for 16 years, MS starts at a mean age of 29, and the disease has only a minimal effect at shortening lifespan, the majority of MS patients presently have progressive forms of MS.  Ten percent have primary progressive disease, progressive from the onset, and others, start with relapsing remitting MS, and progress after approximately 15 years to progressive illness.  In the early years of progressive MS, patients loose the ability to walk, hence the prior motto of the National MS Society, "MS, the great crippler of young adults."  FAMPRIDINE SR IS THE FIRST MEDICATION FOUND TO IMPROVE MS PATIENTS ABILITY TO WALK.  Standard disease modifying agents, the interferons (Avonex, Betaseron, Rebif), Copaxone and Tysabri, decrease relapse rate and may slow progression, however do not improve one's ability to walk.     

NUVIGIL for Jet Lag -- An Important Broad New Indication for Cephalon

June 2, 2009

Cephalon to apply for FDA approval for Nuvigil for jet lag | www.reuters.com

NUVIGIL, Cephalon's single isomer longer effective half-life follow-up product to Provigil is coming to market only after careful strategic planning.  While extremely successful, Provigil, a unique wake promoting agent, suffered in many ways.  When introduced, it had only FDA approval for narcolepsy, a relatively uncommon, yet severe sleep disorder.  Sales increased markedly when Provigil became approved for other common conditions associated with excessive daytime sleepiness (EDS), treated obstructive sleep apnea with residual EDS and sleep wake shift disturbance (SWSD). If approved for Jet Lag, there is the promise that Nuvigil will become available for an increasing enlarging marketplace.

Sequenom's delay

May 4, 2009

UPDATE 2-Sequenom delays Down Syndrome test; shares plunge | uk.reuters.com

This delay is not good for the company, especially since there are already tests in place that are effective to screen for Down's syndrome.  These tests now are the standard of care, so the longer it takes for Sequenon to launch it's test the worse, for the company.

Oral Treprostinil: An effective medicine hiding in a study with a challenging design?

November 18, 2008

Freedom-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint | ir.unither.com

This phase III study was done without the benefit of conventional drug development with Phase I and Phase II studies (which would have provided more information about the effective dose) preceding it because pharmacokinetic date from IV and SC dosing studies were used to extrapolate for the oral dosing. While in hindsight, this may have not been ideal, the trial holds a lot of promise that treprostinil will be effective since there was a nice dose-response curve and the higher doses clearly appeared to be effective. Oral Treprostinil is probably very similar to subcutaneous and intravenous prostanoids (remodulin and flolan) that require a slow uptitration of dose to allow the patient to become tolerant to the side effects. Thus having smaller doses for titration, which were available later in the trial, probably would have allowed for greater success had these doses been available earlier in the study.

"Tamper-Proof" -- A Significant Gain to Whom??

November 17, 2008

FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com

Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect pick up in the marketplace (assuming approval) to be slow.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Other Freestanding Healthcare Facility

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • Medical Director
  • President
  • Director
  • Partner

GLG Live Meetings with this Study Group's Leading Experts (?)

September 25, 2008 | Palo Alto

GLG Seminar: (Palo Alto) Sleep Disorders

July 31, 2007 | Boston

GLGi: Managed Care Formulary

July 30, 2007 | New York

GLGi: Managed Care Formulary

GLG Webcasts & Teleconferences

Leading Experts in Physicians who Treat Insomnia (US) have not participated in any GLG webcasts.

View All GLG Webcasts & Teleconferences in Healthcare